Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, +25

New England Journal of Medicine

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Robert J. Motzer, Paul B. Robbins, Thomas Powles, +20

Nature Medicine

UrologyAxitinib Versus SunitinibGenitourinary CancerMedicinePharmacology +6

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Fiona Blackhall, Kevin Jao, Laurent Greillier, +21

Journal of Thoracic Oncology

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

Toni K. Choueiri, Laurence Albigès, John B.A.G. Haanen, +16

Journal of Clinical Oncology

Renal PathologyImmunologyRenal InflammationPathologyVersus Sunitinib +23

Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study

Lauren A. Byers, Dmitry Bentsion, Steven Gans, +15

Clinical Cancer Research

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park, +175

Annals of Oncology

Metastatic Urothelial CancerUrologyGenitourinary CancerSelect Fgfr AlterationsMedicine +5

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

John B.A.G. Haanen, James Larkin, Toni K. Choueiri, +10

ESMO Open

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

Alessandra Bearz, Jean‐François Martini, Jacek Jassem, +12

Journal of Thoracic Oncology

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial

Toni K. Choueiri, Konstantin Penkov, Hiroji Uemura, +24

Annals of Oncology

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, +17

Annals of Oncology

UrologyOncologyGenitourinary CancerKidney ResearchMedicine +7